The Biotech Voyager

Jeff Martin
  • 0.0 (0)
  • News Commentary
  • Updated Daily

Biotech's Live show. Dedicated to covering the early stage signals that indicate what's next in the industry.

  1. 2d ago

    Scar Tissue Is Blocking Paralyzed Patients

    The Biotech Voyager

  2. 2d ago

    Hundreds of Millions in New Funding! Is Biotech BACK?

    Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD.

  3. Sep 2

    Matricelf's Cell Therapy for Spinal Cord Injury, and the Continued Ascendance of mRNA-LNP

    Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD.

  4. Aug 31

    Interview with Dan Tardiff - CSO of CAMP4 Therapeutics

    Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. Dan Tardiff, Chief Scientific Officer of CAMP4 Therapeutics, joins the show to explain how his company is using antisense oligonucleotides to upregulate gene expression by targeting regulatory RNAs, why haploinsufficient disorders represent the ideal therapeutic window for their platform, and why a modest twofold increase in transcription could transform treatment for rare neurodevelopmental diseases. CAMP4 has developed a novel approach to gene upregulation that targets non-coding regulatory RNAs transcribed from promoters and enhancers rather than the genes themselves. Dan walks through the biology of these regulatory elements, explaining how nearly universal transcription from promoters and enhancers creates a kinetic trap for transcription factors that can be modulated with antisense oligonucleotides. The platform uses genome-wide mapping techniques including chromatin accessibility, histone modifications, and Hi-C sequencing to identify regulatory regions, then confirms RNA expression through long-read sequencing before screening for therapeutic oligonucleotides. The conversation explores why ASOs offer advantages over small molecules and gene therapy for certain indications, how CAMP4's lead program in SYNGAP1-related disorder compares to Stoke Therapeutics' splice-switching approach in Dravet syndrome, the technical challenges of intrathecal delivery versus emerging blood-brain barrier shuttle technologies, and why the company expects to initiate Phase 1/2 clinical trials by the end of the year following regulatory approval in Australia and Argentina. New episodes every Tuesday and Thursday at 11:00 AM. #biotech #CAMP4therapeutics #ASO #genetherapy #CNS #raredisease

  5. Aug 31

    Interview with Rustam Esanov - CEO of Reprogram Bio

    Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. Rustam Esanov, co-founder and CEO of Reprogram Bio, joins the show to explain how his company is transforming cancer cells into allies rather than attacking them directly, why the convergence of single cell sequencing and mRNA delivery makes reprogramming therapeutics possible now, and why he believes reprogramming is the natural evolution of in vivo genetic medicine. Reprogram Bio is developing a novel approach to solid tumor therapy that uses mRNA to deliver master regulator transcription factors directly into tumors. Rather than trying to kill cancer cells or recreate a specific cell type like competitor Asgard Therapeutics, Reprogram Bio activates multiple therapeutic functions within cancer cells themselves, including antigen presentation, immune cell recruitment, and co-stimulation. Rustam walks through their lead program in colorectal and non-small cell lung cancer, explains how their approach differs from other tumor reprogramming strategies, and shares early results showing complete tumor eradication and resistance to cancer rechallenge in mouse models. The conversation explores the biological foundation of cellular reprogramming, the technical challenges of in vivo delivery, potential applications beyond oncology including Parkinson's disease and diabetes, and why reprogramming therapeutics represent the next frontier after in vivo CAR-T. New episodes every Tuesday and Thursday at 11:00 AM. #biotech #reprogrambio #mRNA #celltherapy #oncology #immunotherapy

  6. Aug 28

    Could ASOs be Poised to Greatly Impact Biopharma?

    Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD.

  7. Aug 20

    Turning Cancer Cells into Allies, Moderna News, and Future Therapeutic Development

    Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news.

  8. Aug 19

    Boulevard Bio Emerges, InduPro's ADC Doses First Patient - and Remarkable Therapeutics From Israel

    Welcome to the Biotech Voyager w/ Jeff and Ben. It's the show that covers what's next in biotech.

See All (37)

About

Biotech's Live show. Dedicated to covering the early stage signals that indicate what's next in the industry.

Information

  • Creator
    Jeff Martin
  • Years Active
    2026
  • Episodes
    37
  • Rating
    Clean

You Might Also Like